Volume 13, Number 6—June 2007
Economic Evaluation and Catheter-related Bloodstream Infections
|Intervention||Comparator||Analysis||Perspective||Sensitivity analysis||Time horizon||Hospitalized patients||Ref.|
|MR CVC||CHG-SSD CVC||CUA||HC payer||PROB, OW, SC||Patient lifetime||Adults at high risk for CR-BSI likely to require a triple-lumen, noncuffed CVC for >3 d||27|
|MR CVC and CHG-SSD CVC||Standard CVC||CEA||HC payer||OW, SC, TH||Duration hospitalized||Critically ill patients requiring a CVC expected to be placed >48 h||29|
|CHG-SSD CVC||Standard CVC||CEA||HC payer||PROB, OW, SC, TH||Duration hospitalized||Patients at high risk for catheter-related infections requiring short-term use (2–10 d) of multilumen CVCs||30|
|MSB at CVC insertion||Less stringent asepsis||CEA||Hospital||OW, SC||Duration hospitalized||Patients requiring short-term multilumen CVC (specifically, those in ICU, with immunosuppression, or receiving TPN)||26|
|Skin preparation and dressing|
|CHG skin prep||PI skin preparation||CEA||Hospital||PROB, OW, SC||Duration hospitalized||Patients requiring either a PVC or CVC (considered separately) for short-term use (<10 d)||23|
|CHG dressing||Standard dressing||CEA†||Hospital||OW, MW, SC||Duration hospitalized||Patients at high risk for catheter-related infections requiring short-term use (2–10 d) of multilumen CVCs||24|
|Total parenteral nutrition|
|TPN commercial bags||TPN glass bottles||CMA/CEA||Hospital||MW, TH||Duration hospitalized||Patients receiving TPN through catheter for severe bowel dysfunction secondary to Crohn disease, medical ICU patients, and surgical ICU patients||25|
|Optimal CVC change regimen (10 d, 5 d)||3-d change regimen||CEA||Hospital||OW, MW, TH||Duration catheterized||65-year-old man in ICU with reversible disease process||28|
*Except for the study in reference 25, which used a regression model, all studies used a decision tree. CR-BSI, catheter-related bloodstream infections; Ref., reference; MR, minocycline and rifampicin; CVC, central venous catheter; CHG-SSD, chlorhexidine gluconate/silver sulfadiazine; CUA, cost-utility analysis; HC, healthcare; PROB, probabilistic sensitivity analysis; OW, one way; SC, scenario; CEA, cost-effectiveness analysis; TH, threshold; MSB, maximal sterile barriers; ICU, intensive-care unit; TPN, total parenteral nutrition; PI, povidone-iodine; CMA, cost-minimization analysis; MW, multi way.
†Crawford et al. (24) identified their evaluation as a cost-benefit analysis (CBA) but they conducted a cost-effectiveness analysis with health outcomes multiplied by a dollar value to produce a monetary valuation of health benefits.
- National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–85.
- O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Guidelines for the prevention of intravascular catheter-related infections. MMWR Recomm Rep. 2002;51(RR-10):1–29.
- Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg. 2001;136:229–34.
- Blot SI, Depuydt P, Annemans L, Benoit D, Hoste E, de Waele JJ, Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis. 2005;41:1591–8.
- Eggimann P, Sax H, Pittet D. Catheter-related infections. Microbes Infect. 2004;6:1033–42.
- Harbarth S, Sax H, Gastmeier P. The preventable proportion of nosocomial infections: an overview of published reports. J Hosp Infect. 2003;54:258–66.
- Gastmeier P, Geffers C. Prevention of catheter-related bloodstream infections: analysis of studies published between 2002 and 2005. J Hosp Infect. 2006;64:326–35.
- Graves N, Halton K, Lairson D. Economics and preventing hospital-acquired infection—broadening the perspective. Infect Control Hosp Epidemiol. 2007;28:178–84.
- Saint S, Chenoweth C, Fendrick M, Arbor A. The role of economic evaluation in infection control. Am J Infect Control. 2001;29:338–44.
- Organization for Economic Co-operation and Development (OECD). The OECD Factbook 2006. Brussels: The Organization; 2006.
- Kuntz K, Weinstein M. Modelling in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care. Merging theory with practice. Oxford (UK): Oxford University Press; 2001.
- Sculpher MJ, Drummond M, McCabe C. Whither trial-based economic evaluation for healthcare decision making? Health Econ. 2006;15:677–87.
- Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control. 2005;33:501–9.
- Stone PW, Larson E, Kawar LN. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990–2000. Am J Infect Control. 2002;30:145–52.
- Heyland DK, Kernerman P, Gafni A, Cook DJ. Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Crit Care Med. 1996;24:1591–8.
- Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ. When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. Crit Care Med. 2006;34:2738–47.
- Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976–1997. Ann Intern Med. 2000;132:964–72.
- Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8:1–158.
- Cooper N, Coyle D, Abrams KR, Mugford M, Sutton AJ. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy. 2005;10:245–50.
- Coyle D, Lee KM. Evidence-based economic evaluation: how the use of different data sources can impact results. In: Donaldson C, Mugford M, Vale L, editors. Evidence-based health economics: from effectiveness to efficiency in systematic review. London: BMJ Publishing Group; 2002. p. 55–66.
- Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Oxford Centre for evidence-based medicine levels of evidence. Oxford (UK): Centre for Evidence-based Medicine; 2001.
- Clarke M, Oxman AD. The Cochrane reviewers handbook 4.1.6. Oxford (UK): The Cochrane Collaboration; 2003.
- Chaiyakunapruk N, Veenstra DL, Lipsky BA, Sullivan SD, Saint S. Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine. Clin Infect Dis. 2003;37:764–71.
- Crawford AG, Fuhr JP, Rao B. Cost-benefit analysis of chlorhexidine gluconate dressing in the prevention of catheter-related bloodstream infections. Infect Control Hosp Epidemiol. 2004;25:668–74.
- Durand-Zaleski I, Delaunay L, Langeron O, Belda E, Astier A, Brun-Buisson C. Infection risk and cost-effectiveness of commercial bags or glass bottles for total parenteral nutrition. Infect Control Hosp Epidemiol. 1997;18:183–8.
- Hu KK, Veenstra DL, Lipsky BA, Saint S. Use of maximal sterile barriers during central venous catheter insertion: clinical and economic outcomes. Clin Infect Dis. 2004;39:1441–5.
- Marciante KD, Veenstra DL, Lipsky BA, Saint S. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control. 2003;31:1–8.
- Ritchey NP, Caccamo LP, Carter KJ, Castro F, Erickson BA, Johnson W, Optimal interval for triple-lumen catheter changes: a decision analysis. Med Decis Making. 1995;15:138–42.
- Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters. Chest. 2003;124:275–84.
- Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA. 1999;282:554–60.
- McConnell SA, Gubbins PO, Anaissie EJ. Are antimicrobial-impregnated catheters effective? Replace the water and grab your washcloth, because we have a baby to wash. Clin Infect Dis. 2004;39:1829–33.
- Sonnenberg FA, Roberts MS, Tsevat J. Toward a peer review process for medical decision analysis models. Med Care. 1994;32(Suppl):JS52–64.
- Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954–61.
- Graves N, Weinhold D. Complexity and the attribution of cost to hospital-acquired infection. In: Roberts JA, editor. Economics and infectious diseases. Oxford (UK): Oxford University Press; 2006.
- Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics. 2000;17:461–77.
- Harris AD, Lautenbach E, Perencevich E. A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. Clin Infect Dis. 2005;41:77–82.
- Ades AE. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Stat Med. 2003;22:2995–3016.
- Briggs AH. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care, merging theory with practice. 3rd ed. Oxford (UK): Oxford University Press; 2001.
- Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet. 2002;360:711–5.